BAY 869766,
BAY-869766,
BAY869766,
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide,
RDEA 119,
RDEA-119,
RDEA119,
refametinib,
Refametinib,
923032-37-5,
RDEA119,
BAY 869766,
RDEA 119,
BAY 86-9766,
UNII-JPX07AFM0N,
RDEA-119,
JPX07AFM0N,
Refametinib (RDEA119, Bay 86-9766),
(S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide,
BAY 86-97661,
N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide,
Refametinib R enantiomer,
Refametinib [INN],
BAY-869766,
BAY 8697661,
3e8n,
Refametinib; RDEA119,
Refametinib (RDEA119),
SCHEMBL345333,
C19H20F3IN2O5S,
GTPL7942,
Refametinib (BAY86-9766),
CHEMBL1236682,
DTXSID40238961,
RDSACQWTXKSHJT-NSHDSACASA-N,
AOB87134,
EX-A2481,
2254AH,
MFCD18633256,
s1089,
ZINC39187987,
AKOS025401896,
CS-1818,
SB16881,
BAY-86-9766,
RDEA119(BAY 869766),
NCGC00188380-01,
NCGC00188380-02,
NCGC00188380-03,
4CA-0257,
AC-26962,
AS-16994,
Cyclopropanesulfonamide, N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-((2S)-2,3-dihydroxypropyl)-,
HY-14691,
SW218136-2,
J3.661.482J,
Z-3246,
BAY 869766;BAY 86-97661;RDEA-119;RDEA119,
(S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide,
N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide,
N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[(2S)-2,3-dihydroxypropyl]cyclopropanesulfonamide,
RDEA-119 S enantiomer|||BAY-86-9766 S enantiomer|||N-[3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide,
VRA,
D03SKL,
BAY869766,
B1034,
B1267,
A11264,
C544830,
923032-38-6,
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide,